Antoni Ribas

Antoni Ribas, MD, PhD, is Professor of Medicine, Surgery, and Molecular & Medical Pharmacology at UCLA, Director of the Tumor Immunology Program at Jonsson Comprehensive Cancer Center, and Director of the Parker Institute for Cancer Immunotherapy Center at UCLA. A Spanish-born immunologist, Dr. Ribas is internationally recognized for establishing pembrolizumab as first-in-class anti-PD-1 immunotherapy for melanoma. Dr. Ribas was instrumental in pembrolizumab (Keytruda) clinical development. As key investigator in the landmark 2013 NEJM Phase 1 trial (PMID 23724846, 8,000+ citations), he helped demonstrate lambrolizumab produced 38% confirmed response rate in advanced melanoma with durable responses. He subsequently led KEYNOTE-006, the pivotal Phase 3 trial (NEJM 2015, PMID 25891173, 9,500+ citations) showing pembrolizumab superiority over ipilimumab in PFS and OS, leading to FDA approval. A pioneer of combination strategies, Dr. Ribas authored the first-in-human trial combining BRAF+MEK inhibitors with PD-1 blockade in BRAF-mutant melanoma (Nat Med 2019, PMID 31171879). This triple combination demonstrated 16-month median PFS versus 10.3 months with targeted therapy alone, establishing feasibility of combining targeted and immune therapies. Dr. Ribas advanced understanding of immunotherapy resistance, discovering JAK1/2 mutations associated with acquired PD-1 resistance and IFN-γ signaling's role in primary resistance. His research on oncolytic virotherapy with T-VEC plus pembrolizumab (Cell 2017) pioneered new combination approaches. Elected to National Academy of Medicine (2020) and recognized as AACR and SITC Fellow, Dr. Ribas received the 2021 Society for Melanoma Research Lifetime Achievement Award, 2020 ESMO Translational Research Award, 2019 Coley Award, 2018 AACR-CRI Lloyd J. Old Award, and 2015 Giants of Cancer Care Award.

Antoni Ribas医学博士、哲学博士现任UCLA医学、外科和分子与医学药理学教授、Jonsson综合癌症中心肿瘤免疫学项目主任以及Parker癌症免疫治疗研究所UCLA中心主任。Ribas博士出生于西班牙，因确立pembrolizumab作为首个anti-PD-1黑色素瘤免疫治疗药物而享誉国际。 Ribas博士在pembrolizumab (Keytruda)临床开发中发挥关键作用。作为2013年NEJM Phase 1试验的关键研究者(PMID 23724846, 引用8,000+次)，他帮助证明lambrolizumab在晚期黑色素瘤中产生38%确诊缓解率并具有持久反应。他随后领导KEYNOTE-006这一里程碑Phase 3试验(NEJM 2015, PMID 25891173, 引用9,500+次)，证明pembrolizumab在PFS和OS上优于ipilimumab，促成FDA批准。 作为联合治疗策略先驱，Ribas博士撰写了首个在BRAF突变黑色素瘤中联合BRAF+MEK抑制剂与PD-1阻断的人体试验(Nat Med 2019, PMID 31171879)。这一三联疗法显示中位PFS 16个月相比靶向治疗单独10.3个月，确立了靶向与免疫治疗联合的可行性。 Ribas博士推进了免疫治疗耐药机制的理解，发现与获得性PD-1耐药相关的JAK1/2突变以及IFN-γ信号在原发耐药中的作用。他关于溶瘤病毒T-VEC联合pembrolizumab的研究(Cell 2017)开创了新的联合方法。 Ribas博士2020年当选美国国家医学院院士，获认AACR和SITC会士，获2021年黑色素瘤研究学会终身成就奖、2020年ESMO转化研究奖、2019年Coley奖、2018年AACR-CRI Lloyd J. Old奖和2015年Giants of Cancer Care奖。